| Trial | Title | Study Record Detail | Phase | Sponsor/ Collaborator |
|---|---|---|---|---|
| Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS | NCT02706899 | I & II | Seattle Genetics, Inc. | |
| A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | NCT02614560 | I & II | Seattle Genetics, Inc. | |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE) | NCT02785900 | III | Seattle Genetics, Inc. | |
| A Safety Study of SGN-CD33A in AML Patients | NCT01902329 | I | Seattle Genetics, Inc. | |
| A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | NCT02326584 | I | Seattle Genetics, Inc. |
Last Editorial Review: June 19, 2017
